Neoadjuvant therapy for high-risk localized prostate cancer

被引：1
作者：
Evan Y. Yu
William K. Oh
机构：
[1] Lank Center for Genitourinary Oncol., Department of Medical Oncology, Harvard Medical School, Boston, MA 02115
来源：
Current Oncology Reports | 2003年 / 5卷 / 3期
关键词：
Prostate Cancer; Docetaxel; Radical Prostatectomy; Lycopene; Gleason Score;
D O I：
10.1007/s11912-003-0118-3
中图分类号：
学科分类号：
摘要：
Prostate cancer patients with clinical stage T3 disease, biopsy Gleason scores of 8 to 10, or serum prostate-specific antigen levels greater than 20 ng/mL are at high risk of recurrence despite local therapy. Although hormonal therapy has palliative benefit for the majority of patients with metastatic disease, randomized trials have not demonstrated a survival benefit for its administration prior to surgery for locally advanced disease. Historically, chemotherapy has been felt to have little activity in hormone-refractory prostate cancer, but new evidence may refute this belief. Ongoing clinical trials are now investigating the use of chemotherapy in the neoadjuvant setting. We review the recent literature regarding the use of neoadjuvant hormonal manipulation, chemotherapy, and promising new molecular targeted agents in patients with high-risk localized prostate cancer. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：250 / 257
页数：7
相关论文
共 55 条
[1]  
D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, pp. 969-974, (1998)
[2]  
D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer, J. Clin. Oncol., 18, pp. 1164-1172, (2000)
[3]  
Labrie E., Cusan L., Gomez J., Et al., Neoadjuvant hormonal therapy: The Canadian experience, Urology, 49, SUPPL. 3A, pp. 56-64, (1997)
[4]  
Soloway M.S., Sharifi R., Wajsman Z., Et al., Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer, J. Urol., 154, pp. 424-428, (1995)
[5]  
Van Poppel H., De Ridder D., Elgamal A.A., Et al., Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial, J. Urol., 154, pp. 429-434, (1995)
[6]  
Goldenberg S.L., Klotz L.H., Srigley J., Et al., Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer, J. Urol., 156, pp. 873-877, (1996)
[7]  
Schulman C.C., Debruyne F.M., Forster G., Et al., 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer, Eur. Urol., 38, pp. 706-713, (2000)
[8]  
Hugosson J., Abrahamsson P.A., Ahlgren G., Et al., The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment, Eur. Urol., 29, pp. 413-419, (1996)
[9]  
Dalkin B.L., Ahmann F.R., Nagle R., Et al., Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer, J. Urol., 155, pp. 1357-1360, (1996)
[10]  
Vailancourt L., Ttu B., Fradet Y., Et al., Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study, Am. J. Surg. Pathol., 20, pp. 86-93, (1996)
123456